MSDC-0602K

立即咨询

MSDC-0602K

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

1314533-27-1

包装与价格：

包装	价格(元)
5mg	询价
10mg	询价
25mg	询价
50mg	询价

Azemiglitazone potassium

MSDC-0602K (Azemiglitazone potassium) 是一种噻唑烷二酮类化合物，与PPARγ结合，IC₅₀为 18.25 μM。MSDC-0602K 调节线粒体丙酮酸载体 (MPC)。MSDC-0602K 可用于脂肪肝的研究，包括功能失调的脂质代谢、炎症和胰岛素抵抗。MSDC-0602K 是一种胰岛素 (insulin) 增敏剂，单独或与 Liraglutide 联合使用可改善小鼠的胰岛素血症和脂肪肝疾病。

生物活性

MSDC-0602K (Azemiglitazone potassium), aPPARγ-sparing thiazolidinedione (Ps-TZD), binds toPPARγwith theIC₅₀of 18.25 μM^[1]. MSDC-0602K modulates the mitochondrial pyruvate carrier (MPC). MSDC-0602K can be used for the research of fatty liver including dysfunctional lipid metabolism, inflammation, andinsulinresistance^[2]. MSDC-0602K, aninsulinsensitizer, improves insulinemia and fatty liver disease in mice, alone and in combination with Liraglutide^[3].

IC₅₀& Target^[1]

PPAR-γ

18.25 μM (IC₅₀)

体内研究
(In Vivo)

Diabeticdb/dband MS-NASH mice are treated with MSDC-0602K by oral gavage, Liraglutide by s.c. injection, or combination MSDC-0602K + Liraglutide. This combination treatment may be an effective therapeutic strategy for diabetes and non-alcoholic steatohepatitis (NASH).

Animal Model:	Five-week-old maledb/dbmice on C57BL/6J background and age/sex-matched db/+ control mice^[1]
Dosage:	30 mg/kg MSDC-0602K; 0.2 mg/kg Liraglutide (obtained from MedChemExpress; HY-P0014)
Administration:	MSDC-0602K gavage daily, Liraglutide s.c. injection every other day, or combined MSDC-0602K+ Liraglutide
Result:	MSDC-0602K corrected glycemia and reduced insulinemia when given alone, or in combination with Liraglutide. However, MSDC-0602K + Liraglutide combination more significantly improved glucose tolerance and liver histology.

Clinical Trial

分子量

409.50

Formula

C₁₉H₁₆KNO₅S

CAS 号

1314533-27-1

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.